Bipolar Disorder News and Research

Latest Bipolar Disorder News and Research

Studies suggest potent therapeutic effects of rufinamide in bipolar disorder, depressive and anxiety disorders

This study formulates the hypothesis that rufinamide, a drug so far used against epilepsy, may also be effective in bipolar disorder, depressive and anxiety disorders, panic disorder and obsessive-compulsive disorder, eating disorders, and substance use disorders. It is just an hypothesis based on two cases that needs to be confirmed by specific studies.

19 May 2010

Causes and treatment options of mental disorders need to be reassessed: JAMA commentary

It is time to reassess mental disorders, recognizing that these are disorders of brain circuits likely caused by development processes, according to a commentary in the May 19 issue of JAMA, a theme issue on mental health.

19 May 2010

New research shows link between mental health and creativity

New research shows a possible explanation for the link between mental health and creativity. By studying receptors in the brain, researchers at Karolinska Institutet have managed to show that the dopamine system in healthy, highly creative people is similar in some respects to that seen in people with schizophrenia.

18 May 2010

HHS announces $1 billion in Recovery Act awards for construction, repair and renovation of research facilities

U.S. Department of Health and Human Services Secretary Kathleen Sebelius today announced one billion dollars of American Recovery and Reinvestment Act funds have been awarded to construct, repair and renovate scientific research laboratories and related facilities across the country. The National Institutes of Health (NIH) National Center for Research Resources (NCRR) administered the grants, which are expected to create or sustain jobs nationwide and to help foster scientific advances that may lead to improved human health.

15 May 2010

Off-label use of AAs among elderly associated with increased risk of diabetes: Study

A new study yields important new evidence that the use of atypical antipsychotics among the elderly for off-label purposes is associated with increased risk of developing diabetes.

14 May 2010

Seriously mentally ill are three times more likely to be imprisoned than hospitalized, report finds

USA Today: "On average, a seriously mentally ill person in the USA is three times more likely to be incarcerated than hospitalized, a report concludes today. In no state was a seriously mentally ill person — someone with schizophrenia or bipolar disorder, for example — less likely to be incarcerated than hospitalized, the report by the National Sheriffs' Association and the Treatment Advocacy Center found.

13 May 2010

NARSAD honours UNC's Patrick Sullivan with 2010 Distinguished Investigator Award

Patrick Sullivan, MD has received a 2010 Distinguished Investigator Award from NARSAD for a comparison of genetics in schizophrenia and bipolar disorder.

13 May 2010

Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million

Alexza Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010 and provided a business update.

11 May 2010

Biovail reports 27% increase in first-quarter 2010 total revenues

Biovail Corporation today announced its financial results for the three-month period ended March 31, 2010.

6 May 2010

Two Cardiff University academics elected Fellows of the Academy of Medical Sciences

Two Cardiff University academics, both leaders in different aspects of neuroscience research, have received one of the leading honours in medical science.

6 May 2010

Alexza Pharmaceuticals secures $15M working capital loan from Hercules Technology Growth Capital

Alexza Pharmaceuticals, Inc. announced today that it has executed a $15 million working capital loan agreement with Hercules Technology Growth Capital. The funds available under the loan will be used for capital equipment and working capital purposes. In connection with the loan, Alexza issued Hercules warrants to purchase 376,394 shares of common stock at an exercise price of $2.69 per share, which was the 50-day average daily weighted average trading price at the time the term sheet for the loan was issued by Hercules.

6 May 2010

Alexza Pharmaceuticals announces filing of universal shelf registration statement with SEC

Alexza Pharmaceuticals, Inc. announced today that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow the Company to sell, from time to time, up to $75 million of its common stock, preferred stock, debt securities and/or warrants, either individually or in units, in one or more offerings.

5 May 2010

Beta version of Mental Health Social Network launched

Mental Health Social, LLC launches first beta version of its Mental Health Social Network, announces Colin Spencer Wood, company President and Chief Executive Officer. The beta version includes a new design/layout, an updated status page, added options in the profile, the ability for users to blog on a Word press multi-user blog system, where users have the option of adding their own google adsense ads, and several other site features.

4 May 2010

Mood and anxiety disorders associated with poor health outcomes

Rates of mood and anxiety disorders appear to decline with age but the conditions remain common in older adults, especially women, according to a report in the May issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

4 May 2010

New classification of depressive subtypes of depression proposed

Lichtenberg and Belmaker propose a new classification of depressive subtypes of depression in the current issue of Psychotherapy and Psychosomatics. They argue that a simple diagnosis is no longer sufficient to guide treatment.

3 May 2010

Neuralstem's stem cell treatment for ALS featured on CNN with Dr. Sanjay Gupta

Neuralstem, Inc. announced that its stem cell treatment for ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease), currently in a FDA-approved Phase I clinical trial, was featured on CNN last night with Dr. Sanjay Gupta, in the piece entitled "Stem Cell Medical Breakthrough".

30 Apr 2010

Celtic Pharma commences enrolment in Phase III trial of TDT 067 for onychomycosis

Celtic Pharmaceutical Holdings L.P., the global private equity firm focused on the biotechnology and pharmaceutical industries, announced today the enrolment of the first patient into its Phase III trial of TDT 067, terbinafine in Transfersomes®, for the topical treatment of onychomycosis (also known as a fungal nail infection).

30 Apr 2010

Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder

Repligen Corporation announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder. The patent, which upon issue will remain in force until 2025 prior to any patent term extensions, covers the use of an effective dose of a uridine composition to improve one or more of the symptoms of bipolar disorder including depression, mania, mixed episodes, hypomania and anxiety.

30 Apr 2010

A new approach for treating neurological and degenerative disorders

In studies on cancer, heart disease, neurological disorders and other degenerative conditions, some scientists are moving away from the "nature versus nurture" debate, and are finding you're not a creature of either genetics or environment, but both - with enormous implications for a new approach to health.

29 Apr 2010

Court of Appeals denies McNeil Pediatrics' CONCERTA patent appeal

The Court of Appeals for the Federal Circuit has denied an appeal by McNeil Pediatrics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., to overturn a 2009 decision by the U.S. District Court of Delaware that the patent for CONCERTA (methylphenidate HCl) Extended-Release Tablets CII is invalid and not infringed by Andrx Corporation.

27 Apr 2010

Bipolar Disorder News and Research

Latest Bipolar Disorder News and Research

Studies suggest potent therapeutic effects of rufinamide in bipolar disorder, depressive and anxiety disorders

Causes and treatment options of mental disorders need to be reassessed: JAMA commentary

New research shows link between mental health and creativity

HHS announces $1 billion in Recovery Act awards for construction, repair and renovation of research facilities

Off-label use of AAs among elderly associated with increased risk of diabetes: Study

Seriously mentally ill are three times more likely to be imprisoned than hospitalized, report finds

NARSAD honours UNC's Patrick Sullivan with 2010 Distinguished Investigator Award

Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million

Biovail reports 27% increase in first-quarter 2010 total revenues

Two Cardiff University academics elected Fellows of the Academy of Medical Sciences

Alexza Pharmaceuticals secures $15M working capital loan from Hercules Technology Growth Capital

Alexza Pharmaceuticals announces filing of universal shelf registration statement with SEC

Beta version of Mental Health Social Network launched

Mood and anxiety disorders associated with poor health outcomes

New classification of depressive subtypes of depression proposed

Neuralstem's stem cell treatment for ALS featured on CNN with Dr. Sanjay Gupta

Celtic Pharma commences enrolment in Phase III trial of TDT 067 for onychomycosis

Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder

A new approach for treating neurological and degenerative disorders

Court of Appeals denies McNeil Pediatrics' CONCERTA patent appeal

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Bipolar Disorder News and Research

Latest Bipolar Disorder News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in